Coherus BioSciences, Inc. Stock News

- Oppenheimer Initiates a Robust Process with Global Reach for the Benefit of Shareholders - - Oppenheimer Initiates a Robust Process with Global Reach for the Benefit of Shareholders -

– Entitles holders to receive net proceeds from sale of remaining Legacy Biosimilar Assets – – Completes transformation of Coherus Oncology into a fully integrated, innovative immuno-oncology company – REDWOOD CITY, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) (“Coherus”, “Coherus Oncology” or the “Company”) today announced a special dividend of contingent val...

– LOQTORZI® net revenue of $13.6 million in Q2 2026, up 15% over Q1 – – Clinical data continue to mature across programs with emerging evidence of activity with tagmokitug in head and neck cancer – – Projected October public disclosure of data sets with sufficient maturity – – Conference call today at 5:00 p.m. Eastern Daylight Time – REDWOOD CITY, Calif.

– First patient dosed in a Phase 1 study evaluating ZM008, an anti-LLT1 mAb, in combination with LOQTORZI, a next-generation PD-1 inhibitor – – First patient dosed in a Phase 1 study evaluating ZM008, an anti-LLT1 mAb, in combination with LOQTORZI, a next-generation PD-1 inhibitor –

Coherus Oncology NASDAQ: CHRS said it expects revenue growth for its nasopharyngeal cancer drug LOQTORZI to build through the rest of 2026, while the company prepares for multiple clinical data readouts across its oncology pipeline later this year.

– LOQTORZI® net revenue of $11.8 million in Q1 2026 – – Patient accrual complete for 1L HCC Phase 2 randomized clinical trial for anti-IL27 casdozokitug, timing for data readouts tracking to projections – – Tagmokitug, CCR8 Treg depleter development expands with pharmacological and clinical program differentiation, including dose-responsive immune effects, no off-target binding, acceptable safe...

REDWOOD CITY, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its first quarter 2026 financial results will be released after market close on Monday, May 11, 2026. Starting at 5:00 p.m. Eastern Time on May 11, 2026, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business upd...